Chinese Drugmaker’s IPO Tests a Slumping Biotech Market

  • 📰 WSJ
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

“Anytime you have companies without earnings, people value them based on sentiment.” Investors are still trying to understand the Chinese biotech sector.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Chinese market slump tests index-crafter nervesPlans by FTSE Russell and MSCI to expose a fresh $76 bln to mainland stocks look shaky as Shanghai out-swoons New York. If Beijing reacts clumsily, as in 2015 when it allowed shares to be halted and attacked traders, sceptical investors could be emboldened to revolt.
Source: Breakingviews - 🏆 470. / 51 Read more »